- Home
- LRE vs CASI Comparison
LRE vs CASI Comparison
Compare LRE & CASI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LRE
- CASI
- Stock Information
- Founded
- LRE 2001
- CASI 1991
- Country
- LRE Japan
- CASI China
- Employees
- LRE N/A
- CASI N/A
- Industry
- LRE
- CASI Biotechnology: Pharmaceutical Preparations
- Sector
- LRE
- CASI Health Care
- Exchange
- LRE Nasdaq
- CASI Nasdaq
- Market Cap
- LRE 24.0M
- CASI 20.5M
- IPO Year
- LRE 2023
- CASI 1996
- Fundamental
- Price
- LRE $1.60
- CASI $2.36
- Analyst Decision
- LRE
- CASI Strong Buy
- Analyst Count
- LRE 0
- CASI 1
- Target Price
- LRE N/A
- CASI $4.00
- AVG Volume (30 Days)
- LRE 70.5K
- CASI 3.7M
- Earning Date
- LRE 01-01-0001
- CASI 09-02-2025
- Dividend Yield
- LRE N/A
- CASI N/A
- EPS Growth
- LRE N/A
- CASI N/A
- EPS
- LRE N/A
- CASI N/A
- Revenue
- LRE $110,330,328.00
- CASI $31,368,000.00
- Revenue This Year
- LRE N/A
- CASI N/A
- Revenue Next Year
- LRE N/A
- CASI N/A
- P/E Ratio
- LRE N/A
- CASI N/A
- Revenue Growth
- LRE 3.92
- CASI 8.39
- 52 Week Low
- LRE $1.10
- CASI $1.09
- 52 Week High
- LRE $2.49
- CASI $7.67
- Technical
- Relative Strength Index (RSI)
- LRE 49.41
- CASI 64.70
- Support Level
- LRE $1.44
- CASI $1.95
- Resistance Level
- LRE $1.57
- CASI $3.09
- Average True Range (ATR)
- LRE 0.15
- CASI 0.34
- MACD
- LRE -0.00
- CASI 0.07
- Stochastic Oscillator
- LRE 34.21
- CASI 55.21
About LRE Lead Real Estate Co. Ltd
Lead Real Estate Co Ltd operates as a developer of luxury residential properties, including single-family homes and condominiums, across Tokyo, Kanagawa prefecture, and Sapporo. The company also operates hotels in Tokyo and leases apartment building units to individual customers in Japan and Dallas, Texas. Predominantly, its revenue is generated from developing and selling single-family homes and condominiums. The company's sole operating segment is real estate sales. Geographically, it derives revenue from Japan.
About CASI CASI Pharmaceuticals Inc.
CASI Pharmaceuticals Inc is a biopharmaceutical company that focuses on commercializing therapeutics and pharmaceutical products. The products include injections for patients who are suffering from leukemias and lymphomas. The EVOMELA injection is used as a conditioning treatment before autologous stem cell transplant for patients with multiple myeloma. The company products include CID-103, CNCT19, EVOMELA, MARQIBO, ZEVALIN, ENMD-2076 and others. The majority of the revenue is generated from the product sales of EVOMELA.